Please ensure Javascript is enabled for purposes of website accessibility

Stock Market News: These 2 Rising Stocks Are Solving Coronavirus Challenges

By Dan Caplinger - Apr 16, 2020 at 12:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The overall market was mixed Thursday morning.

The stock market was relatively quiet on Thursday morning, with a lack of volatility that was eerily reminiscent of the days before the coronavirus pandemic threw the global economy into panic. Weekly jobless claims numbers in the U.S. were once again at extremely high levels above 5.2 million, showing the extent of the economic damage that the COVID-19 outbreak has done. As of 11 a.m. EDT, the Dow Jones Industrial Average (^DJI 0.00%) was down 27 points to 23,477. However, the S&P 500 (^GSPC 1.05%) rose 13 points to 2,796, and the Nasdaq Composite (^IXIC 0.00%) gained 120 points to 8,514.

Stocks in many sectors have gotten hurt hard by the coronavirus, but some companies are finding ways to profit by offering their help to their customers. Abbott Laboratories (ABT 1.45%) expects to see a boost to its financial results from making its coronavirus test available to medical professionals. Meanwhile, Slack Technologies (WORK) has benefited from the rise in working from home and people's need to stay connected to their fellow co-workers remotely.

Abbott stays healthy

Shares of Abbott Labs were higher by 4% Thursday morning after the pharmaceutical giant reported its first-quarter financial results. Gains in revenue and adjusted earnings were noteworthy, but investors were really excited about the prospects for future sales from coronavirus-related products and services.

Person wearing blue gloves holding a pill, with a bunch of other pills on a glass table.

Image source: Getty Images.

Abbott's numbers were solid. Revenue climbed 2.5% from year-ago levels on a 4.3% rise in organic sales. Adjusted earnings came in at $0.65 per share, up 3% year over year. Gains were largest in Abbott's established pharmaceutical division, and results in the nutrition segment were also strong. Those gains made up for relative weakness in medical devices, especially within the U.S. market.

The company's ID Now and m2000 RealTime diagnostic tests for COVID-19 have been a key part of Abbott's response to the coronavirus pandemic. Along with a blood test to detect the IgG antibody, Abbott is seeing huge demand for these products, and it expects that medical professionals will continue to want the fast results that its array of tests offers.

Just about the only bad news was that Abbott chose to withdraw its guidance for 2020, citing uncertainties about the impact of the coronavirus on its entire business. Nevertheless, with prospects for growth related to COVID-19, investors have high hopes for Abbott's stock.

This stock's not Slacking

Shares of Slack Technologies were up 6% as investor appetite for stocks related to the work-from-home movement continued to gain traction. Slack hasn't performed all that well since its debut on the public markets almost a year ago, but it's bounced significantly from its lows from before the coronavirus crisis began.

Slack's software-as-a-service workplace collaboration platform has made it easier for workers in all locations to work together more effectively. With messaging services as well as integrated voice, video, and file sharing technology, Slack has increasingly become an important tool that large enterprises and small businesses are using to improve productivity and transparency.

Moreover, Slack has identified the importance of working to bolster its growth now. A recent move to raise money through a convertible debt offering helped strengthen its balance sheet, giving Slack the financial resources it'll need to make smart strategic moves.

Slack has acknowledged that it won't be immune from coronavirus-imposed economic challenges, with enterprise customers potentially looking for ways to cut back on expenses. Nevertheless, with a lot of interest from businesses trying to stay productive during the outbreak, Slack hopes to see the surge in its growth continue even once things get closer to normal.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$110.22 (1.45%) $1.57
Slack Technologies, Inc. Stock Quote
Slack Technologies, Inc.
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$30,775.43 (0.00%) $0.00
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
$3,825.33 (1.05%) $39.95
NASDAQ Composite Index (Price Return) Stock Quote
NASDAQ Composite Index (Price Return)
$11,028.74 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.